



# Ask us about Pre-ANDA Communication Pathways!

## **Robert Lionberger, PhD**

Director  
Office of Research and Standards  
Office of Generic Drugs  
CDER | U.S. FDA



## **Karen Bengtson**

Supervisory Regulatory Health Project Manager  
Office of Research and Standards  
Office of Generic Drugs  
CDER | U.S. FDA

## **Maria Monroy-Osorio**

Regulatory Health Project Manager  
Office of Research and Standards  
Office of Generic Drugs  
CDER | U.S. FDA

## **Irfan Memon, PharmD**

Regulatory Health Project Manager  
Office of Research and Standards  
Office of Generic Drugs  
CDER | U.S. FDA

## **Steven Yang, PharmD**

Regulatory Business Project Manager  
Office of Program and Regulatory Operations  
Office of Pharmaceutical Quality  
CDER | U.S. FDA

## **Qinghua Ge, MS**


Senior Regulatory Business Project Manager  
Office of Program and Regulatory Operations  
Office of Pharmaceutical Quality  
CDER | U.S. FDA

## **Onyekachukwu Ihezie, PharmD**

Regulatory Business Project Manager  
Office of Program and Regulatory Operations  
Office of Pharmaceutical Quality  
CDER | U.S. FDA

# GDUFA III Pre-ANDA Scientific Meetings

FDA



# GDUFA III Pre-ANDA Scientific Meetings: Product Development and Pre-Submission Meetings



**Facilitate communications between FDA and prospective applicants related to complex products and/or complicated drug development questions**

Product Development (PDEV) Meetings  
Pre-submission (PSUB) Meetings



# GDUFA III Pre-ANDA Scientific Meetings: Product-Specific Guidance Teleconferences and Meetings



Can be requested when FDA publishes a new or revised guidance that introduces or revises a recommendation and:

- Recommendation is related to an in vivo bioequivalence (BE) study
- ANDA applicant has already commenced an in vivo BE study that may be different from product-specific guidance (PSG) recommendations as of the published date for the new or revised PSG

PSG Teleconference  
Pre-submission PSG Meeting<sup>1</sup>



<sup>1</sup> Following a PSG T-con, a PSG meeting can be requested to discuss scientific rationale for an approach other than the approach recommended in the PSG

# Additional Pre-ANDA Scientific Meetings

FDA

**Additional Pre-ANDA Scientific Meetings available not covered under GDUFA III that may be more suitable for your program needs.**

Parallel Scientific Advice (PSA) Pilot Program for Complex/Hybrid Products



Model-Integrated Evidence (MIE) Industry Meeting Pilot



## Refer to

- [FDA-EMA Parallel Scientific Advice Pilot Program for Complex Generic/Hybrid Products Webpage](#)
- [Expanding Generic Drug Access Through International Engagements Webinar](#)
- [Model-Integrated Evidence \(MIE\) Industry Meeting Pilot Between FDA and Generic Drug Applicants Webpage](#)
- [A Deep Dive: FDA's Model-Integrated Evidence \(MIE\) Industry Meeting Pilot Program for Generic Drugs Webinar](#)

# Controlled Correspondence or PDEV Meeting?

## Controlled correspondence (CC)

- Single or small group of closely related questions
- Questions outside of PDEV scope
- Response within 60 days (Level 1) or 120 days (Level 2)



## PDEV Meeting

- Falls under will or may grant situation
- Multiple or multi- disciplinary questions
- New information, data, or questions not suitable for a CC
- Response within 120 days of PDEV being granted



*Do not submit the same questions through a CC and PDEV meeting around a similar timeframe*

# Product-Specific Guidance

**Reflects FDA's current thinking and expectations on how to develop a generic drug product therapeutically equivalent to a specific reference listed drug (RLD)**



# Upcoming Product-Specific Guidances for Generic Drug Product Development



---

Guidances | Drugs

---

Product-Specific  
Guidances for Generic  
Drug Development

---

Guidance Snapshot Pilot

---

## Introduction

This web page provides information related to upcoming new and revised product-specific guidances (PSGs) to support the development and approval of safe and effective generic drug products, including the projected date of PSG publication, as a commitment under the [Generic Drug User Fee Amendments of 2022 \(GDUFA III\)](#). Upcoming PSGs for both complex and non-complex products that are planned to be published in the next 12 months are listed (these may be subject to change).

## How often does FDA publish new and revised PSGs?

To support generic drug development and generic drug approval, FDA issues new and revised PSGs on a quarterly and as needed basis. These PSGs, including PSGs for both complex and non-complex generic drug products, when finalized, describe the agency's current thinking and expectations on how to develop generic drug products to specific reference listed drugs and are intended to assist the generic pharmaceutical industry with identifying the most appropriate methodology and evidence needed to support a specific generic drug's approval. The [published PSGs](#) are announced in the Federal Register and made available to the public on FDA's website.

---

Content current as of:  
09/13/2024

Regulated Product(s)  
Drugs  
Generic Drugs





We care about enhancing  
access to generic drugs

| WE ARE THE **GENERIC DRUG PROGRAM**